Veradigm (MDRX) – StreetInsider.com Reports
-
Deutsche Bank Downgrades Veradigm Inc (MDRX) to Hold
-
Increasing unusual call option volume: SOUN BCS MDRX DEO VIPS AXON SPLK SHLS D URBN
-
Veradigm (MDRX) Dropped from S&P SmallCap 600
-
Veradigm (MDRX) Mentioned as Short at Bleecker Street Research
-
Veradigm (MDRX) Receives Nasdaq Delisting Notice
-
Increasing unusual option volume: BBAI SOUN ATUS BMBL SPLK PUBM MDRX ATMU HIMS MGNI IAU
-
Veradigm (MDRX) to Acquire ScienceIO
-
Increasing unusual call option volume: GLBE MDRX OCGN WING CHK INDI SOUN CRNT
-
Veradigm Inc (MDRX) PT Lowered to $11 at RBC Capital
-
Veradigm Inc (MDRX) PT Lowered to $10 at Piper Sandler
-
Barclays Starts Veradigm Inc (MDRX) at Equalweight
-
Veradigm (MDRX) Acquires Koha Health
-
Veradigm (MDRX) Announces that Nasdaq Hearings Panel has Granted its Continued Listing
-
Veradigm (MDRX) Announces Greg Garrison Named Executive Chairman; Dr. Shih-Yin Ho Appointed Interim CEO; Lee Westerfield Appointed Interim CFO
-
Veradigm (MDRX) Receives Nasdaq Notice Regarding Delayed Form 10-Q
-
Veradigm (MDRX) Announces Receipt of Nasdaq Stay Extension
-
Veradigm (MDRX) Announces Receipt of Nasdaq Delisting Notice and Intent to Appeal
-
Argus Downgrades Veradigm Inc (MDRX) to Hold, 'shares appear fairly valued'
-
Veradigm Inc (MDRX) PT Lowered to $18 at Deutsche Bank
-
Veradigm (MDRX) Increases Presence in Payer Market
-
Veradigm (MDRX) Receives Nasdaq Approval of Plan to Regain Listing Compliance
-
Veradigm (MDRX) Receives Nasdaq Non-compliance Notice
-
Stephens Starts Veradigm Inc (MDRX) at Equal Weight
-
Veradigm Inc (MDRX) PT Lowered to $13 at Piper Sandler
-
Veradigm (MDRX) Receives Nasdaq Notice Regarding Delayed Form 10-K Filing, Provides Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results
-
Piper Sandler Downgrades Veradigm Inc (MDRX) to Neutral
-
Veradigm (MDRX) Announces $250M Share Buyback, Guides FY23
-
Veradigm (MDRX) Reports Q4 Results
-
Veradigm (MDRX) Acquires Stake in Holmusk
-
Allscripts (MDRX) Rebrands as Veradigm
-
Argus Upgrades Allscripts (MDRX) to Buy
-
Allscripts (MDRX) PT Raised to $20 at JPMorgan
-
Allscripts (MDRX) PT Raised to $23 at Goldman Sachs
-
Allscripts (MDRX) PT Raised to $21 at Deutsche Bank
-
Allscripts (MDRX) PT Raised to $21 at Deutsche Bank Following Modest 'Beat'
-
Piper Sandler Reinstates Allscripts (MDRX) at Overweight
-
Allscripts (MDRX) Tops Q3 EPS by 4c
-
Allscripts (MDRX) PT Lowered to $20 at Deutsche Bank
-
Allscripts (MDRX) Reaffirms FY22 Guidance (earlier)
-
KeyBanc Starts Allscripts (MDRX) at Sector Weight
-
Amedisys (AMED), Allscripts (MDRX), Others Mentioned as 'Read-Throughs' at Cowen on Signify Health (SGFY) Bidding War
-
Goldman Sachs Starts Allscripts (MDRX) at Neutral
-
UPDATE: Allscripts (MDRX) PT Lowered to $23 but BofA Securities Sees MSD Growth with Margin Upside
-
Allscripts (MDRX) PT Lowered to $17 at Piper Sandler
-
Allscripts (MDRX) Misses Q1 EPS by 10c; Affirms Outlook
-
Allscripts (MDRX) PT Raised to $22 at Piper Sandler
-
Allscripts (MDRX) PT Raised to $23 at CFRA
-
UPDATE: Deutsche Bank Upgrades Allscripts (MDRX) to Buy
-
Allscripts (MDRX) to Sell the Net Assets of Its Hospitals & Large Physician Practices Business Segment to Constellation Software
-
Allscripts (MDRX) PT Raised to $26 at Cowen
Back to MDRX Stock Lookup